NLRP3 and heart failure: Canakinumab, conversely, demonstrated the ability to block NLRP3 inflammasome and IL-1β activations, highlighting IL-1-targeted therapy potential in preventing the recurrence of atherosclerotic thrombotic events and heart failure happening (38).